At Avidity, we are developing a new class of oligonucleotide-based therapies. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. We hope that our AOC therapies can treat a wide range of serious diseases and our initial focus is on muscle diseases.
Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.
Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.
Location: United States, California, La Jolla
Employees: 51-200
Total raised: $301M
Founded date: 2013
Investors 7
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.06.2020 | IPO | $150M | - |
| 13.11.2019 | Series C | $100M | - |
| 22.04.2019 | - | $35M | - |
| 05.01.2017 | Series B | $16M | - |
Mentions in press and media 26
| Date | Title | Description |
| 17.07.2026 | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. Fri, Jul 17, 2026 08:00 CET Report this content 17 July 2026 THE BIOTECH GROWTH TRUST PLC (“BIOG” or the "Company") Eli Lilly to acquire BIOG portfolio company, AtaiBec... |
| 27.03.2026 | Швейцарская фармкомпания Novartis купит американскую биотехкомпанию Excellergy за $2 млрд | Novartis планирует приобрести американскую биотехнологическую компанию Excellergy за сумму до $2 млрд, делая ставку на препарат нового поколения для лечения аллергии, который, как ожидается, будет действовать быстрее и эффективнее существую... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 27.10.2025 | European markets end higher with Fed meeting, Trump-Xi summit in focus | LONDON — European stocks were higher on Monday as traders look ahead to the U.S. Federal Reserve’s meeting, more earnings and signs of a rapprochement between Washington and Beijing. The pan-European Stoxx 600 preliminarily closed Monday’s ... |
| 27.10.2025 | Швейцарская Novartis покупает американскую биотехнологическую компанию Avidity за $12 млрд | Компания Novartis AG согласилась приобрести Avidity Biosciences Inc. за $12 млрд, что стало крупнейшей сделкой швейцарского производителя лекарств за последние более чем десять лет. Приобретение добавляет несколько потенциальных препаратов-... |
| 27.10.2025 | Novartis Agrees to Acquire Avidity Biosciences, an Innovator in Rna Therapeutics, Strengthening Its Late-Stage Neuroscience Pipeline | announced that it has entered into an agreement to acquire Avidity Biosciences, a San Diego-based, biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle. The acquisition will follow the separation ... |
| 27.10.2025 | Wall Street rallies toward more records as gold’s price slumps again | By STAN CHOE, AP Business Writer NEW YORK (AP) — Stocks are climbing toward more records on Monday ahead of a week packed with potentially market-moving events for Wall Street. The S&P 500 rose 1%. The Dow Jones Industrial Average was u... |
| 27.10.2025 | 5 Things to Know Trump’s trade deals, Novartis acquires Avidity, Taco Bell’s beverage push and more in Morning Squawk | President Donald Trump penned several trade agreements ahead of his expected meeting with China leader Xi Jinping later this week. Novartis announced it will buy Avidity Biosciences. Taco Bell has been opening Live Más Cafés inside its rest... |
| 26.10.2025 | Novartis ‘nears’ deal to acquire Avidity Biosciences for more than $70/share, says report | - |
| 26.10.2025 | Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash | Swiss pharmaceutical giant Novartis has agreed to buy biotechnology company Avidity Biosciences for about $12 billion, the company said Sunday. Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Fr... |
Show more